

Metropolis Healthcare Ltd. records 26% YoY growth in non-covid revenue* for Q1FY23 to Rs. 262 Crs.

Total B2C Revenue grew by 28% YoY in Q1FY23

Q1FY23 Key Highlights

- Non-Covid Home Visits revenue increased by 30% YoY Rs. 23 Crs.
- Specialized tests contributed 42% to the Non-Covid revenue
- EBITDA margin (Before CSR & ESOP) stood at 25.6%

Mumbai, August 10, 2022: Metropolis Healthcare Ltd. (NSE: METROPOLIS | BSE: 542650) - a leading diagnostic service provider - announced its unaudited consolidated financial results today for the first quarter of financial year 2023.

Q1FY23 Financial Highlights

Rs. 261.7 Crs.

Non Covid Revenue*

Rs. 71.7 Crs.

EBITDA (Before CSR & ESOP)

Rs. 33.6 Crs.

Profit After Tax

*Revenue excl. covid PCR & covid allied tests

“I am extremely pleased to share that we have recorded 26% growth on year-on-year basis for non-covid business inspite of the challenging business environment. Covid and Covid allied revenue witnessed a sharp fall as expected in line with the drop in number of covid cases. Going ahead, we expect the non-covid revenue to revert back to the sustainable growth rates recorded in pre-covid days.

We at Metropolis will continue to build our scientific capabilities, expand our network of labs and patient collection centres, build a superior customer experience, and will also focus on wellness and chronic testing segment. We are excited about the differentiation we have been able to create over the years and believe our company has a long runway of growth.”

Ameera Shah, Promoter and Managing Director, Metropolis Healthcare Ltd.

ACCREDITATIONS FOR METROPOLIS

The Global Reference Laboratory of Metropolis holds accreditation from the College of American Pathologists (CAP) since 2005 which is the gold standard in accreditations in our industry, globally.

Our clinical laboratories hold one or more of CAP, NABL, KENAS, ILAC or APLAC accreditations.

(CAP: College of American Pathologists; NABL: National Accreditation Board for Testing and Calibration Laboratories; KENAS: Kenya Accreditation Service; ILAC: International Laboratory Accreditation Cooperation, APLAC: Asia Pacific Laboratory Accreditation Cooperation)

RECENT AWARDS AND ACCOLADES

Our MD, Ms. Ameera Shah recognized as the Most Promising Women Leader of India 2022 by ET x Femina.

Metropolis bagged the 'Innovation in Patient Centricity and Advocacy' Award at the Patient First Summit 2022 by IHW (India Health & Wellness Council) for introducing the holistic comprehensive package 'PREGASCREEN'

Metropolis awarded with the 'Most Popular Diagnostic Laboratory Award' at the Healthcare Excellence Awards from CNH Care for demonstrating excellence in customer service based on user reviews.

Metropolis honoured with the 'Best of Bharat – Pride of India Brands' Award from Exchange4media.

Our MD Ms Ameera Shah honoured with the 'Outstanding Healthcare Leader of the Year' Award at the Women Achievers Award 2022, hosted by Abhyudaya Vatsalyam, acknowledging contribution and efforts in the healthcare sector.

Our CFO Mr. Rakesh Agarwal honoured with the FE CFO Year of the Award at the 5th edition of FE CFO Awards for his outstanding achievements, best practices and excellence.

Metropolis honoured with the Best Organizations for Women, 2022 by the Economic Times.

Our MD Ms Ameera Shah honoured with the 'Most Powerful Woman in Business Award by Business Today

Our MD Ms. Ameera Shah won the Women Entrepreneur Award in Organizational Segment - Health & Wellness category at the Express Awards for Women Entrepreneurs (ExpressAWE), instituted by the Financial Express and FICCI FLO.

In INR Crs.	Q1FY23	Q1FY22
Revenue from Operations	279.9	326.8
EBIDTA (before CSR & ESOP)	71.7	105.6
EBIDTA margin (before CSR & ESOP)	25.6%	32.3%
Profit After Tax	33.6	63.0*
PAT Margin (%)	12.0%	19.3%

*Normalized PAT on account of exceptional gain on settlement with Global Hospital of past dues

About Metropolis: Metropolis Healthcare Ltd is a leading diagnostics company in India with a widespread presence across 20 states in India. Metropolis touches millions of lives each year by providing actionable health insights to patients and doctors. Metropolis offers a comprehensive range of 4000 plus tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities. Metropolis' commitment to quality and accuracy in each test is reinforced by its consistent CAP proficiency score of more than 98% over the past decade, which places it amongst the top 1% laboratories worldwide for quality assurance. Metropolis philosophy rests on the pillars of technological superiority, a warm patient centric approach and reliable diagnostic reports. For more, please visit www.metropolisindia.com or click on [Twitter](#), [Facebook](#), or [LinkedIn](#).

Safe harbor statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

Company: Metropolis Healthcare Ltd.

CIN -L73100MH2000PLC192798

Mr. Jeyasingh Balakrishnan – Head PR and Corporate Communications

jeyasingh.b@metropolisindia.com

www.metropolisindia.com

Investor Relations Advisors: Strategic Growth Advisors Pvt. Ltd.

CIN: U74140MH2010PTC204285

Mr. Shogun Jain / Mr. Shrenik Shah

shogun.jain@sgapl.net / shrenik.shah@sgapl.net